Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,200 across all filing types
Latest filing 2022-05-25 Regulatory Filings
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Recording of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the audio recording of an earnings call for the quarter and financial year ended March 31, 2022. It references the earnings call and provides a link to the audio recording, but does not contain the actual financial results or detailed financial data. The document is short (1392 characters) and serves as an announcement or notification about the earnings call recording rather than the transcript or the earnings release itself. According to the classification rules, a full transcript of the call would be classified as CT, but this is only an announcement of the recording. The document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement that does not fit other categories and is not the earnings release or transcript itself.
2022-05-25 English
General updates
Share Issue/Capital Change Classification · 95% confidence The document is a letter addressed to stock exchanges announcing the grant of stock options under the company's ESOP plan. It details the number of options granted, the exercise price, vesting period, and exercisability terms. This is a clear announcement related to share-based compensation and capital changes, specifically the issuance of stock options. It is not a full report, financial statement, or regulatory filing but an update on capital structure changes. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length is short and focused on this specific capital change, supporting this classification with high confidence.
2022-05-24 English
Financial Result Updates
Annual Report Classification · 95% confidence The document is a detailed communication from Strides Pharma Science Limited dated May 24, 2022, reporting the audited financial results for the quarter and year ended March 31, 2022. It includes financial highlights, quarterly and yearly performance data, management commentary, and operational updates. The document references the approval of audited financial statements and includes an auditor's report. It also contains detailed financial tables and management discussion on business performance and outlook. The presence of comprehensive financial data and auditor's report indicates this is the actual financial report for the fiscal year, not merely an announcement or press release. Therefore, this document fits the definition of an Annual Report (10-K equivalent) for the company covering the full fiscal year ending March 31, 2022. FY 2022
2022-05-24 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is a notification about an upcoming earnings call scheduled for May 25, 2022, to discuss the audited financial results for the quarter and year ended March 31, 2022. It includes dial-in details and mentions that the transcript will be posted on the company's website. The document does not contain actual financial data or the transcript itself, but rather serves as an announcement for the earnings call event. Therefore, it is not the earnings release or the call transcript but an announcement related to the earnings call. Given the options, the best fit is 'Call Transcript (CT)' if it were the transcript, but since this is an announcement of the call, it aligns more with a Regulatory Filing (RNS) as a general announcement. However, since the document specifically announces the earnings call event, the closest specific category is 'Call Transcript (CT)' as it relates directly to the earnings call, but since it is not the transcript itself, the fallback is Regulatory Filings (RNS). The document length is short (2700 characters), supporting it being an announcement rather than a full report. Hence, the classification is Regulatory Filings (RNS) with high confidence.
2022-05-23 English
Board Meeting — Dividend/Financial results
Board/Management Information Classification · 95% confidence The document is a formal announcement addressed to stock exchanges regarding a scheduled Board Meeting to consider and approve audited financial results for the quarter and year ended March 31, 2022, and dividend recommendation. It references Regulation 29 of SEBI Listing Regulations, which pertains to disclosures about board meetings. The document does not contain the financial results themselves but informs about the upcoming meeting where these results will be approved. The document length is short (1263 characters) and serves as a notification rather than a report. Therefore, it is best classified as a Board/Management Information filing, which covers announcements about board meetings and related management decisions.
2022-05-16 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges and a press agency clarifying a news item about Stelis Biopharma's Sputnik Light vaccine stock situation. It contains no financial statements, no regulatory filings, no voting results, no management changes, no earnings data, or any other typical financial report content. It is a public clarification or statement related to a news report, not a formal financial or regulatory filing. The document length is about 5,385 characters, which is relatively short and primarily textual without financial data. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The best fit is Regulatory Filings (RNS) as a general announcement or clarification that does not fit other categories.
2022-05-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.